Cassava Sciences | PTIE - Cash And Equivalent


Cassava Sciences reported $106.08M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Abbott USD 7.51B 560M Sep/2025
Amgen USD 9.13B 316M Dec/2025
Biogen USD 3.86B 1.1B Sep/2025
Cassava Sciences USD 106.08M 6.3M Sep/2025
Eisai JPY 285.38B 19.82B Jun/2025
Eli Lilly USD 9.79B 6.42B Sep/2025
Geron USD 79.99M 389K Sep/2025
J&J USD 18.23B 10.35B Sep/2025
Merck USD 18.17B 10.16B Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Roche Holding CHF 7.55B 579M Jun/2025